IN8bio, Inc.
INAB
Positions held
Your positionsINAB isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $13.60M | Enterprise value | -$2.17M | Trailing P/E | — | Forward P/E | -1.45 |
| PEG | — | Price / book | 0.74 | Beta | 0.30 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -111.1% | ROA | -58.4% | Debt / equity | 0.12 |
| Current ratio | 8.21 | Free cash flow | -$7.92M | Analyst recommendation | none | Mean target | $7.00 |
| 52w high | $2.73 | 52w low | $0.88 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$4.8M | -$5.1M | -$4.9M | -$3.9M | -$5.1M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$4.9M | -$5.3M | -$5.0M | -$4.0M | -$5.2M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$19.4M | -$30.4M | -$30.0M | -$28.5M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$19.9M | -$29.6M | -$30.0M | -$28.5M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-09-22 · IN8bio to Present at Sidoti Small-Cap Virtual Conference
2026-09-10 · IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
2026-09-09 · IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
2026-08-10 · IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-08-06 · IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Price (daily)
Full chart · RSI · MACD · patterns